Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial
T Konert, WV Vogel, D Paez, A Polo, E Fidarova, H Carvalho, PS Duarte, AC Zuliani, AO Santos, D Altuhhova, L Karusoo, R Kapoor, A Sood, J Khader, A Al-Ibraheem, Y Numair, S Abubaker, C Soydal, T Kutuk, TA Le Show all
European Journal of Nuclear Medicine and Molecular Imaging | SPRINGER | Published : 2019
PURPOSE: Patients with stage III non-small-cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT) in low- and middle-income countries (LMIC) continue to have a poor prognosis. It is known that FDG PET/CT improves staging, treatment selection and target volume delineation (TVD), and although its use has grown rapidly, it is still not widely available in LMIC. CRT is often used as sequential treatment, but is known to be more effective when given concurrently. The aim of the PERTAIN study was to assess the impact of introducing FDG PET/CT-guided concurrent CRT, supported by training and quality control (QC), on the overall survival (OS) and progression-free survival (PFS) of patients wi..View full abstract
The International Atomic Energy Agency, Vienna, Austria, funded all meetings of national country coordinators, data collection and processing for this project.